<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169141</url>
  </required_header>
  <id_info>
    <org_study_id>LC-20</org_study_id>
    <nct_id>NCT02169141</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis Patients</brief_title>
  <official_title>Pharmacokinetics of Levofloxacin and Capreomycin in MDR-TB Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Republican Scientific and Practical Centre for Pulmonology and TB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Public Health and the Environment (RIVM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label observational pharmacokinetic drug study to evaluate Levofloxacine and
      Capreomycin in patients with Multidrug-Resistant Tuberculosis (MDR-TB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive MDR-TB treatment with o.a. Levofloxacin and Capreomycin. At least one week
      after start of treatment, the PK samples samples will be obtained via an intravenous catheter
      at 0, 1, 2, 3, 4, 7, and 12 hours after intake.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AUC/MIC ratio of Levofloxacin</measure>
    <time_frame>after day 8 of treatment</time_frame>
    <description>The primary outcome parameter is the ratio of the in vitro minimum inhibitory concentration (MIC) to the area under the serum concentration-time curve (AUC) over 24 hours (AUC0-24h ), [AUC0-24h /MIC], after administration of Levofloxacin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax/MIC ratio of Capreomycin</measure>
    <time_frame>after day 8 of treatment</time_frame>
    <description>The primary outcome parameter is the ratio of the in vitro minimum inhibitory concentration (MIC) to the maximum serum concentration, [Cmax/MIC], after administration of Capreomycin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution</measure>
    <time_frame>after day 8 of treatment</time_frame>
    <description>Based on the measured drug concentration during the dosing interval and patient characteristics (height, bodyweight and age) the volume of distribution will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>after day 8 of treatment</time_frame>
    <description>Based on the drug concetrations during the dosing interval and patient characteristics (height, bodyweight, age) the drug clearance will be calculated</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PK-model</measure>
    <time_frame>after day 8 of treatment</time_frame>
    <description>A population PK model will be developed using an iterative 2-stage Bayesian procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Limited sampling strategy</measure>
    <time_frame>after day 8 of treatment</time_frame>
    <description>Limited sampling strategies were investigated subsequently using a Bayesian analysis. The best possible strategies for will be evaluated by a Bland-Altman analysis for correlation of predicted and observed AUC0-24.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>PK of Levofloxacin-Capreomycin</arm_group_label>
    <description>Pharmacokinetics (PK) in M/XDR-TB patients receiving at least Levofloxacin and Capreomycin as part of their WHO treatment for M/XDR-TB</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacokinetics</intervention_name>
    <description>multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters</description>
    <arm_group_label>PK of Levofloxacin-Capreomycin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        MDR-TB patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt; 18yrs

          -  culture positive

          -  diagnosis of MDR-TB

        Exclusion Criteria:

          -  DM2

          -  Pregnancy

          -  allergy to IV canula material

          -  insertion of IV canula not possibele
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JW C Alffenaar, PhD PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Republican Scientific and Practical Center for TB and Pulmonology</name>
      <address>
        <city>Minsk</city>
        <zip>220053</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>JWC Alffenaar</investigator_full_name>
    <investigator_title>PhD PharmD Clinical Pharmacologist Associate Professor</investigator_title>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>MDR-TB</keyword>
  <keyword>Levofloxacin</keyword>
  <keyword>Capreomycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Capreomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

